The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.
TL;DR
The findings indicate a shift towards more effective and tailored treatments, and future efforts must focus on biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances into practice and improve patient outcomes.
OpenAlex 토픽 ·
Bladder and Urothelial Cancer Treatments
Urinary and Genital Oncology Studies
Urinary Bladder and Prostate Research
The findings indicate a shift towards more effective and tailored treatments, and future efforts must focus on biomarker validation, strategic sequencing, and managing combination toxicities to integr
APA
Yan Hiu Athena Lee, Chris Ming-Ho Wong, et al. (2026). The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.. Current opinion in urology, 36(3), 244-249. https://doi.org/10.1097/MOU.0000000000001388
MLA
Yan Hiu Athena Lee, et al.. "The future of urothelial carcinoma: a 2024-2025 update of early-phase trials of novel therapeutic agents.." Current opinion in urology, vol. 36, no. 3, 2026, pp. 244-249.
PMID
41861349
Abstract
[PURPOSE OF REVIEW] The treatment landscape for advanced and non-muscle-invasive urothelial carcinoma (UC) is rapidly evolving beyond platinum chemotherapy and immune checkpoint inhibitors. This review is timely and relevant as it synthesizes recent, impactful data from 2024-2025 early-phase trials, highlighting agents poised to redefine clinical standards.
[RECENT FINDINGS] Recent studies showcase promising novel strategies. These include next-generation targeted therapies like sapanisertib, novel antibody-drug conjugates (ADCs) and bicycle toxin conjugates (BTCs) such as zelenectide pevedotin (BT8009) and dual-ADC combinations with high response rates, and the approved immunomodulator N-803 for BCG-unresponsive disease. Furthermore, innovative intravesical therapies, including ADCs (disitamab vedotin) and immune checkpoint inhibitors, show transformative potential for localized disease with favorable safety.
[SUMMARY] The findings indicate a shift towards more effective and tailored treatments. Future efforts must focus on biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances into practice and improve patient outcomes.
[RECENT FINDINGS] Recent studies showcase promising novel strategies. These include next-generation targeted therapies like sapanisertib, novel antibody-drug conjugates (ADCs) and bicycle toxin conjugates (BTCs) such as zelenectide pevedotin (BT8009) and dual-ADC combinations with high response rates, and the approved immunomodulator N-803 for BCG-unresponsive disease. Furthermore, innovative intravesical therapies, including ADCs (disitamab vedotin) and immune checkpoint inhibitors, show transformative potential for localized disease with favorable safety.
[SUMMARY] The findings indicate a shift towards more effective and tailored treatments. Future efforts must focus on biomarker validation, strategic sequencing, and managing combination toxicities to integrate these advances into practice and improve patient outcomes.
MeSH Terms
Humans; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Molecular Targeted Therapy; Antineoplastic Agents; Immune Checkpoint Inhibitors; Clinical Trials as Topic; Immunoconjugates; Forecasting